The death of 22-year-old Cole Schmidtknecht highlights a critical flaw in the US healthcare system. His asthma medication, Advair Diskus, experienced a drastic price increase due to Pharmacy Benefit Managers (PBMs) manipulating formularies to maximize profits. This resulted in Cole lacking preventative medication, leading to a fatal asthma attack. His parents are now suing OptumRx and Walgreens, advocating for legislation requiring advanced notice of formulary changes and increased transparency within the PBM system. The Schmidtknechts’ tragedy underscores the urgent need for reform to prevent similar preventable deaths.
Read More
President Trump recently claimed to have invented the word “equalize,” despite its centuries-long existence, while announcing a new executive order aiming to lower prescription drug prices by 80% through price negotiation or government-set limits based on international prices. This order mandates a 30-day deadline for drugmakers to comply. Separately, he expressed fondness for the term “groceries,” highlighting its “old-fashioned” appeal. These pronouncements occurred amidst recent policy announcements and speeches.
Read More
President Trump announced an executive order aiming to slash US prescription drug prices by 30-80%, potentially impacting global markets. This aggressive move involves pressuring European countries to increase their drug prices and threatening trade sanctions against uncooperative nations. The order seeks to lower prices to global minimums, forcing pharmaceutical companies to significantly reduce their profits and potentially reducing investment in research and development. This action is facing opposition from the pharmaceutical industry and analysts question its feasibility.
Read More
Health Secretary Robert F. Kennedy Jr. publicly stated that President Trump received $100 million from Big Pharma, yet asserted the president remained uninfluenced. This declaration, made during a White House press conference announcing a prescription drug price reduction executive order, sparked immediate controversy. While RFK Jr. seemingly intended to highlight Trump’s resistance to pharmaceutical industry pressure, the subsequent rise in pharmaceutical stocks and expert commentary suggest the executive order may lack significant impact or serve as a distraction from other political matters. The event left many questioning the true intentions and potential consequences of the announcement.
Read More
President Trump’s latest executive order, aiming to align U.S. prescription drug prices with those of other developed nations, mirrors a previously blocked attempt and faces similar legal challenges. Senators Sanders and Wyden, along with Representative Khanna, argue that legislative action, rather than unilateral executive orders, is the only viable path to meaningful price reform. They cite the likelihood of pharmaceutical industry legal challenges and propose bipartisan legislation to achieve comparable drug pricing. This approach contrasts with Trump’s past actions, including delaying Medicare price negotiations.
Read More
President Trump announced a new executive order aiming to slash prescription drug prices by 30-80%, implementing a “Most Favored Nation” policy to align US prices with the lowest worldwide prices. This action, to be signed the following morning, seeks to address the significant disparity between US and international drug costs. The policy’s effectiveness, however, faces uncertainty regarding its enforceability on the private sector, with critics questioning its feasibility and potential legal challenges. Trump’s initiative has garnered both praise and skepticism, highlighting the complexities of regulating pharmaceutical pricing.
Read More
A Wisconsin man tragically died after the cost of his inhaler unexpectedly skyrocketed by $500, according to a lawsuit filed by his family. This dramatic price increase allegedly stemmed from OptumRx, a UnitedHealth Group subsidiary, abruptly terminating coverage for the inhaler the man had relied on for a decade. The situation highlights the devastating consequences of the increasingly unaffordable cost of essential medications in the United States.
The lawsuit underscores a critical flaw in the healthcare system; the unpredictable nature of medication costs can leave individuals vulnerable and desperate. The sheer magnitude of the price jump—a five hundred dollar increase—is staggering, placing an insurmountable burden on many patients.… Continue reading
Trump’s first week in office saw the immediate repeal of numerous Biden-era executive orders, most notably Executive Order 14087 aimed at lowering prescription drug costs. This repeal eliminated programs intended to reduce generic drug prices and expand Affordable Care Act enrollment, prompting swift condemnation from Democrats. The Democrats criticized this action as a betrayal of Trump’s campaign promises and evidence of favoritism towards large pharmaceutical companies. They intend to highlight this reversal of healthcare policies to the public, despite their limited legislative power to counteract Trump’s actions.
Read More
Drugmakers are set to raise prices on over 250 medications in the US starting January 1st. This news has unsurprisingly sparked widespread outrage and frustration, especially given the timing – just as many are facing economic challenges. The increases, it’s important to note, apply to list prices. These are the prices before rebates and discounts are factored in, meaning pharmacy benefit managers and other intermediaries will likely still receive significant concessions while consumers bear the brunt of the increase.
This raises immediate questions about fairness and accessibility. Many have voiced concerns that those who rely on these medications for chronic or rare conditions will struggle to afford the higher costs, potentially facing life-altering consequences.… Continue reading
Despite their differing political views, Senator Bernie Sanders and Elon Musk surprisingly find common ground on Pentagon spending and prescription drug prices. Both have criticized the Pentagon’s repeated audit failures and billions in unaccounted spending, advocating for greater fiscal responsibility. Furthermore, they share a commitment to lowering the exorbitant costs of medications like Ozempic and Wegovy, citing the ethical implications of price gouging. This unexpected alignment highlights a potential area for bipartisan cooperation, though their broader political differences remain.
Read More
John Q. Hosedrinker 
Matt Underwood